-
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart J – Corrective and Preventive Action (§820.100 CAPA). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart K – Labeling and Packaging Control (§820.120 Device labeling, §820.130 Device packaging). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart L – Handling, Storage, Distribution, and Installation (§820.140, §820.150, §820.160, §820.170). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart M – Records (§820.180 General requirements, §820.181 Device master record, §820.184 Device history record, §820.186 Quality system record, §820.198 Complaint files). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart N – Servicing (§820.200) and Subpart O – Statistical Techniques (§820.250). Form 483 observations and Warning Letters 2017–2025. -
Sale!
Comprehensive framework for ALCOA++ compliance and regulatory expectations in data integrity programs. -
Sale!
Essential framework for pharmaceutical manufacturing excellence through comprehensive microbiological contamination control strategies and best practices. -
Sale!
Strategic guide to change control as enabler of innovation aligned with FDA QMSR and ISO 13485:2016 requirements. -
Sale!
Strategic insights on design controls, cybersecurity, and QMSR transition for medical device manufacturers navigating AI-enabled technologies. -
Sale!
Strategic approach to medical device quality system improvements addressing QMSR harmonization and cybersecurity requirements. -
Sale!
Framework for establishing and implementing KPIs to drive quality management system continuous improvement and organizational excellence. -
Sale!
FDA regulatory trends and risk management strategies for clinical development of drugs and devices.


